A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Status
- TERMINATED
- Phase
- PHASE2
De-Escalation Therapy for Human Papillomavirus Negative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
- Status
- COMPLETED
- Phase
- PHASE2
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
- Status
- WITHDRAWN
- Phase
- PHASE1
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2